Business / Finance

RSS

TSO3 obtains purchase orders from the US for STERIZONE sterilization system

TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has received purchase orders for multiple devices from the US. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and the Company.

24 Jul 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

The Gladstone Institutes announces the creation of Cure Network Ventures Inc. and Cure Network Dolby Acceleration Partners, LLC, a business endeavor with Dolby Family Ventures and Evotec AG, which will focus on Alzheimer's disease. Working through Cure Network Ventures, Inc., the new company will help expedite the translation of relevant scientific discoveries from the Gladstone Institute of Neurological Disease into the development of potential therapies.

24 Jul 2015

NeoGraft selects Verasoni Worldwide as marketing communications partner

NeoGraft is pleased to announce the selection of Verasoni Worldwide as integrated marketing communications partner. NeoGraft is a world leader in hair replacement technology serving physicians and patients in the United States and around the world. NeoGraft is the first Class One FDA Listed automated medical device for hair restoration.

23 Jul 2015

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).

23 Jul 2015

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma's Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively.

23 Jul 2015

Lupin enters into definitive agreement to acquire GAVIS

Pharma Major Lupin Limited has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc., subject to certain closing conditions, in a transaction valued at USD 880 million, cash free and debt free.

23 Jul 2015

ADPT generates systemwide net patient services revenue of $104.5 million for Q2 2015

Adeptus Health Inc., the largest operator of freestanding emergency rooms in the U.S., announced its results for the second quarter ended June 30, 2015.

23 Jul 2015

NeoGenomics' revenue increases 18% to $24.3 million in second quarter 2015

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2015.

23 Jul 2015

Quest Diagnostics' second quarter revenue grows by 1.2% to $1.93 billion

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that for the second quarter ended June 30, 2015, adjusted net income was $170 million compared to $157 million for 2014. Adjusted diluted EPS excluding amortization was $1.25 in the second quarter of 2015, compared to $1.19 in 2014. Amortization expense per diluted share was $0.08 in the second quarter of 2015 and $0.11 in 2014.

From Quest Diagnostics 23 Jul 2015

Danaher's revenue for second quarter 2015 increases 3.5% to $5.1 billion

Danaher Corporation today announced record results for the second quarter 2015. For the quarter ended July 3, 2015, non-GAAP adjusted diluted net earnings per share were $1.08, which reflects the adjustments identified in the attached reconciliation schedule. On a GAAP basis, diluted net earnings for the second quarter were $696 million, or $0.97 per share. Revenue for the second quarter 2015 increased 3.5% to $5.1 billion with core revenues also increasing 3.5%.

23 Jul 2015

Veeva OpenData services now available in Italy

Today, Veeva Systems announced that it has acquired Merqurio's healthcare professional (HCP) and healthcare organisation (HCO) database for Italy. With the acquisition of this market-leading Italian HCP and stakeholder data, Veeva OpenData now expands to a third major European market and builds on Veeva's commitment to deliver a new approach to customer reference data that is open, easy, and global.

23 Jul 2015

Enigma, Beijing Leadman sign agreement for MiniLab molecular diagnostic Point-of-Care platform

Enigma Diagnostics Ltd. and Beijing Leadman Biochemistry Co., Ltd. signed a joint venture agreement with the principal goal of delivering the Enigma MiniLab molecular diagnostic Point-of-Care platform into the Chinese health care market to support its growing diagnostic needs.

23 Jul 2015

MediCollector to commercialize Wyss Institute's bedside data-acquisition software

The Wyss Institute for Biologically Inspired Engineering at Harvard University today announced that its bedside data-acquisition software will be commercialized by a recently formed startup company, MediCollector LLC. The announcement follows a worldwide license agreement between Harvard's Office of Technology Development and MediCollector.

23 Jul 2015

Perrigo signs agreement to acquire Naturwohl Pharma

Perrigo Company plc today announced that it has entered into an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is expected to generate approximately €30 million in full year 2015 net sales.

22 Jul 2015

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

22 Jul 2015

Compliance - Hear from CCO from Lundbeck, Daiichi Sankyo and Novartis

With tightening transparency requirements the pharmaceutical industry is under increasing pressure to ensure fully compliant communication and interactions through all areas of their business functions. How can you evolve current business practices to build a real cross functional, promotional compliance organisation?

21 Jul 2015

DigiPharm- Meet the who’s who in digital and multichannel marketing

Marketing is not working well enough to serve the needs of the industry or the changing expectations of the patient. It is time to analyse what we are doing well, and where we need to invest effort and embrace genuine customer engagement. It’s time to embrace innovative technologies, improve standard practice and roll out more valuable technologies when justified and create truly integrated, inspiring multichannel engagement campaigns.

21 Jul 2015

Check-Cap provides corporate update, reports financial results for second quarter 2015

Check-Cap Ltd., a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced financial results for the second quarter, ended June 30, 2015.

21 Jul 2015

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Dauntless Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC today announced a licensing agreement providing Dauntless' access to Aegis' Intravail drug delivery technology for an undisclosed oncology application and an option for three additional drugs.

21 Jul 2015

Business / Finance

TSO3 obtains purchase orders from the US for STERIZONE sterilization system

3SBio purchases entire equity interest in Zhejiang Wansheng

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

NeoGraft selects Verasoni Worldwide as marketing communications partner

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

SutroVax completes $22 million Series A financing

Lupin enters into definitive agreement to acquire GAVIS

ADPT generates systemwide net patient services revenue of $104.5 million for Q2 2015

NeoGenomics' revenue increases 18% to $24.3 million in second quarter 2015

Quest Diagnostics' second quarter revenue grows by 1.2% to $1.93 billion

Danaher's revenue for second quarter 2015 increases 3.5% to $5.1 billion

Veeva OpenData services now available in Italy

Enigma, Beijing Leadman sign agreement for MiniLab molecular diagnostic Point-of-Care platform

MediCollector to commercialize Wyss Institute's bedside data-acquisition software

Perrigo signs agreement to acquire Naturwohl Pharma

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

Compliance - Hear from CCO from Lundbeck, Daiichi Sankyo and Novartis

DigiPharm- Meet the who’s who in digital and multichannel marketing

Check-Cap provides corporate update, reports financial results for second quarter 2015

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News